# A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

> **NCT06649214** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 654 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Olanzapine-samidorphan；
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT06649214
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2026-04
- **Final completion:** 2026-05
- **Target enrollment:** 654 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649214, "A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06649214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*